Document Type: Research article
Molecular and Microbiology Research Laboratory, Environmental Biotechnology Division, School of Bio Sciences and Technology, VIT University, Vellore - 632 014, Tamilnadu, India.
The current study was carried out to evaluate the in-vitro and in-vivo efficiency of alpha
glucosidase inhibitor of marine actinobacteria in the control of postprandial hyperglycaemia.
Soil samples were collected from salterns, coastal area in Kothapatnam, Ongole, Andhra
Pradesh, India. Among the actinobacterial isolates tested for yeastα-glucosidase inhibitory
activity, only three isolates showed prominent inhibition. The patient isolate was selected
and identified as Streptomyces coelicoflavus SRBVIT13 using 16S r-RNA gene sequencing.
In in-vitro studies, the chloroform extract of Streptomyces coelicoflavus SRBVIT13 showed
significant enzyme inhibitory activity against yeast and mammalian α-glucosidaseenzymes.
In animal studies, the oral ingestion of chloroform extract (600 mg/kg) of S. coelicoflavus
SRBVIT13 in maltose and sucrose loaded diabetic rats, showed significant regulation of
postprandial blood glucose by 82.25% and a 77.25% reduction, respectively. The lead
compound from S. coelicoflavusSRBVIT13 was isolated, purified, characterized, and identified
by stranded analytical techniques as 2-t-butyl-5-chloromethyl-3-methyl-4-oxoimidazolidine-
1-carboxylic acid, t-butyl ester. The results obtained in the present study are promising and the
bioactive compound from S. coelicoflavusSRBVIT13 may be considered as a potential agent in
regulating the postprandial hyperglycaemia.